Thiogenesis Therapeutics held annual and special shareholder meeting

• Thiogenesis Therapeutics Corp. held its annual and special shareholder meeting on Sept. 8, 2026.
• Shareholders backed all items presented, including the appointment of directors to serve until the next annual meeting.
• MNP LLP was reappointed as auditor until the next annual meeting or until a successor is appointed.
• Disinterested shareholders adopted an amendment to the 2024 Omnibus Equity Incentive Plan; the filing did not confirm implementation steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thiogenesis Therapeutics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609210400NEWSFILECNPR____20260921_315046_1) on September 21, 2026, and is solely responsible for the information contained therein.